Clostridioides Difficile Infection
VIDEO: Patients ‘might fall through the cracks’ between FMT, live microbiota therapies
In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted benefits of newly available live biotherapeutics for Clostridioides difficile infection but noted concern for patients who don’t qualify and “might fall through the cracks.”
VIDEO: ‘Future is now here’ for recurrent C. difficile, thanks to live biotherapeutics
VANCOUVER, British Columbia — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics.
VIDEO: Rebyota ‘not only shuts down recurrence,’ also affects quality of life in C. diff
VANCOUVER, British Columbia — In this Healio video, Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection.
FMT future ‘still being written,’ ideally with more options for recurrent C. difficile
From the early days of homemade “poop shakes” blended in a backroom 15 years ago to the current world of FDA-approved live biotherapeutic products, it feels like we are at an inflection point with fecal microbiota transplantation.
Fecal transplant ‘not over yet’ for C. difficile despite boom in live microbiota therapies
Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often both its cause and its cure.
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
An FDA-approved oral fecal microbiota therapeutic reduces the risk for recurrent Clostridioides difficile infection in high-risk patients compared with placebo, regardless of demographics or baseline risk factors, researchers reported.
VIDEO: ‘Robust’ data analysis establishes safety of Rebyota for recurrent C. difficile
In a Healio video exclusive, Lindy Bancke, PharmD, outlines results from the “largest safety evaluation to date” for Rebyota, the first FDA-approved, microbiota-based treatment for prevention of recurrent Clostridioides difficile infection.
Hospital lowers rate of nosocomial C. difficile with revised approach
ORLANDO — A hospital reduced the rate of hospital-onset cases of Clostridioides difficile infection with a standardized system for early recognition and testing, researchers found.
Two-step testing associated with decreased incidence of hospital-onset C. difficile
Two-step Clostridioides difficile testing was associated with decreased reported incidence of hospital-onset C. difficile infection and C. difficile-specific antibiotic use, researchers found.
Digestive Disease Week roundup: Colorectal cancer data dominated; what else did you miss?
Digestive Disease Week 2023 in Chicago may have ended in early May, but Healio coverage has continued all month long. Wondering what you missed and what is coming next? Healio recaps the biggest meeting news making waves in the specialty.